InMed Pharmaceuticals (INM) FCF Margin (2021 - 2025)
InMed Pharmaceuticals (INM) posted quarterly FCF Margin of 289.72% for Q4 2025, down 6465.0% year-over-year from 4.55% in Q4 2024, and down 101.86% quarter-over-quarter from 143.52% in Q3 2025.
InMed Pharmaceuticals (INM) FCF Margin (2021 - 2025) Analysis & Trends
InMed Pharmaceuticals' FCF Margin history runs 5 years deep, the most recent figure standing at 289.72% for Q4 2025.
- In Q4 2025, FCF Margin fell 6465.0% year-over-year to 289.72%; the TTM figure through Dec 2025 stood at 164.69% (down 1348.0% YoY), while the FY2025 annual figure was 157.14%, down 500.0% from the prior year.
- FCF Margin for Q4 2025 stood at 289.72%, down from 143.52% in the prior quarter.
- The five-year high for FCF Margin was 35.63% in Q2 2023, with the low at 1236.47% in Q4 2021.
- The 5-year median for FCF Margin is 166.17% (2024), against an average of 359.34%.
- The sharpest annual moves came in 2023 and 2024: FCF Margin soared 76382 bps in 2023, then plunged 7620 bps in 2024.
- InMed Pharmaceuticals' FCF Margin stood at 1236.47% in 2021, then soared by 53 bps to 577.52% in 2022, then soared by 74 bps to 148.87% in 2023, then plunged by 51 bps to 225.07% in 2024, then slipped by 29 bps to 289.72% in 2025.
- Business Quant data shows INM's FCF Margin at 289.72% in Q4 2025, 143.52% in Q3 2025, and 136.31% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 7.41% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 21.80% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 14.87% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 26.25% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 8.76% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 13.41% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 17.84% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | InMed Pharmaceuticals | 6.36 Mn | 1.11 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -289.72% |
| Sep 30, 2025 | -143.52% |
| Jun 30, 2025 | -136.31% |
| Mar 31, 2025 | -131.54% |
| Dec 31, 2024 | -225.07% |
| Sep 30, 2024 | -144.45% |
| Jun 30, 2024 | -80.21% |
| Mar 31, 2024 | -166.17% |
| Dec 31, 2023 | -148.87% |
| Sep 30, 2023 | -240.73% |
| Jun 30, 2023 | -35.63% |
| Mar 31, 2023 | -160.23% |
| Dec 31, 2022 | -577.52% |
| Sep 30, 2022 | -701.41% |
| Jun 30, 2022 | -799.46% |
| Mar 31, 2022 | -891.37% |
| Dec 31, 2021 | -1,236.47% |